Amplexd Therapeutics

Executive Summary

Amplexd Therapeutics is a patient-scientist led biotech company developing non-invasive treatments for HPV-induced cervical intraepithelial neoplasia (CIN), a precursor to cervical cancer. Current standard-of-care involves invasive surgical procedures that are costly, require clinical visits, and can cause significant side effects. Amplexd is addressing this unmet need with a portfolio of self-administered topical suppositories and a proprietary photodynamic therapy (PDT) system. These treatments are designed to be accessible, scalable, and patient-friendly, potentially reducing the burden on healthcare systems while improving patient compliance and outcomes. The company’s mission is to provide effective, non-invasive alternatives that prioritize patient safety and experience, targeting a significant public health issue affecting millions of women worldwide. Founded in 2020 and based in San Diego, Amplexd is leveraging its proprietary platform to develop treatments for early-stage cervical lesions. The company’s approach combines drug delivery expertise with photodynamic therapy, offering a dual strategy to maximize efficacy and convenience. While still in early stages, Amplexd’s focus on topical, self-administered therapies positions it uniquely in the women’s health and oncology space. The success of its clinical development could establish a new standard of care for CIN, reducing progression to invasive cancer and improving quality of life for patients. With a compelling value proposition and a strong scientific foundation, Amplexd Therapeutics represents a promising opportunity in the biotech landscape.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 clinical trial for lead topical suppository candidate60% success
• Q1 2027FDA pre-IND meeting for photodynamic therapy (PDT) system70% success
• Q3 2026Publication of preclinical efficacy data in peer-reviewed journal80% success